Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Novabay Pharmaceuticals, Inc. (NBY) since 2007 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Novabay Pharmaceuticals, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1389545.
Total stock buying since 2007: $26,609,962.
Total stock sales since 2007: $4,218,051.
Total stock option exercises since 2007: $191,999.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 516,003 | $322,541 | 0 | $0 | 0 | $0 |
| 2023 | 0 | $0 | 0 | $0 | 5,148 | $0 |
| 2022 | 10,000 | $1,500 | 2,949,440 | $535,630 | 120,000 | $0 |
| 2021 | 1,115,222 | $519,758 | 0 | $0 | 0 | $0 |
| 2020 | 0 | $0 | 1,322,350 | $1,628,890 | 0 | $0 |
| 2019 | 0 | $0 | 468,772 | $1,721,932 | 0 | $0 |
| 2015 | 2,935,332 | $1,759,638 | 0 | $0 | 0 | $0 |
| 2014 | 672,800 | $614,900 | 30,000 | $20,899 | 61,000 | $34,160 |
| 2013 | 15,108,156 | $17,210,316 | 120,000 | $225,000 | 0 | $0 |
| 2012 | 4,579,500 | $5,712,185 | 0 | $0 | 28,500 | $15,960 |
| 2011 | 32,752 | $36,841 | 0 | $0 | 0 | $0 |
| 2010 | 0 | $0 | 15,000 | $27,450 | 18,158 | $36,679 |
| 2009 | 26,000 | $60,150 | 25,000 | $58,250 | 30,000 | $16,800 |
| 2008 | 40,600 | $102,133 | 0 | $0 | 52,000 | $88,400 |
| 2007 | 67,500 | $270,000 | 0 | $0 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-04 | 48,646 | $27,623 | 0 | $0 | 0 | $0 |
| 2025-03 | 235,654 | $144,202 | 0 | $0 | 0 | $0 |
| 2025-02 | 129,315 | $83,038 | 0 | $0 | 0 | $0 |
| 2025-01 | 102,388 | $67,678 | 0 | $0 | 0 | $0 |
| 2023-05 | 0 | $0 | 0 | $0 | 5,148 | $0 |
| 2022-11 | 0 | $0 | 35,760 | $75,270 | 0 | $0 |
| 2022-09 | 10,000 | $1,500 | 2,913,680 | $460,360 | 0 | $0 |
| 2022-05 | 0 | $0 | 0 | $0 | 120,000 | $0 |
| 2021-12 | 872,956 | $408,448 | 0 | $0 | 0 | $0 |
| 2021-11 | 242,266 | $111,310 | 0 | $0 | 0 | $0 |
| 2020-08 | 0 | $0 | 1,322,350 | $1,628,890 | 0 | $0 |
| 2019-06 | 0 | $0 | 468,772 | $1,721,932 | 0 | $0 |
| 2015-08 | 12,000 | $5,640 | 0 | $0 | 0 | $0 |
| 2015-03 | 2,923,332 | $1,753,998 | 0 | $0 | 0 | $0 |
| 2014-12 | 143,000 | $93,630 | 30,000 | $20,899 | 0 | $0 |
| 2014-06 | 4,800 | $4,272 | 0 | $0 | 0 | $0 |
| 2014-05 | 525,000 | $516,998 | 0 | $0 | 0 | $0 |
| 2014-04 | 0 | $0 | 0 | $0 | 52,000 | $29,120 |
| 2014-03 | 0 | $0 | 0 | $0 | 9,000 | $5,040 |
| 2013-12 | 15,000,000 | $17,099,997 | 0 | $0 | 0 | $0 |
| 2013-11 | 108,156 | $110,319 | 0 | $0 | 0 | $0 |
| 2013-09 | 0 | $0 | 120,000 | $225,000 | 0 | $0 |
| 2012-12 | 160,000 | $193,600 | 0 | $0 | 0 | $0 |
| 2012-10 | 3,600,000 | $4,500,000 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-04-08 | Fakhry Jad | Buy | 300 | .47 | 139 |
| 2025-04-04 | Fakhry Jad | Buy | 4,538 | .52 | 2,368 |
| 2025-04-03 | Fakhry Jad | Buy | 22,976 | .56 | 12,935 |
| 2025-04-02 | Fakhry Jad | Buy | 917 | .58 | 531 |
| 2025-04-01 | Fakhry Jad | Buy | 19,915 | .58 | 11,650 |
| 2025-03-31 | Fakhry Jad | Buy | 21,654 | .59 | 12,775 |
| 2025-03-28 | Fakhry Jad | Buy | 49,400 | .61 | 30,232 |
| 2025-03-27 | Fakhry Jad | Buy | 19,104 | .61 | 11,691 |
| 2025-03-26 | Fakhry Jad | Buy | 13,292 | .61 | 8,094 |
| 2025-03-25 | Fakhry Jad | Buy | 22,635 | .61 | 13,807 |
| 2025-03-24 | Fakhry Jad | Buy | 100 | .60 | 60 |
| 2025-03-21 | Fakhry Jad | Buy | 6,372 | .60 | 3,855 |
| 2025-03-20 | Fakhry Jad | Buy | 5,320 | .61 | 3,271 |
| 2025-03-19 | Fakhry Jad | Buy | 1,500 | .60 | 904 |
| 2025-03-18 | Fakhry Jad | Buy | 24,000 | .63 | 15,120 |
| 2025-03-14 | Fakhry Jad | Buy | 25,511 | .63 | 16,071 |
| 2025-03-13 | Fakhry Jad | Buy | 34 | .64 | 21 |
| 2025-03-12 | Fakhry Jad | Buy | 11,837 | .62 | 7,374 |
| 2025-03-11 | Fakhry Jad | Buy | 2,148 | .58 | 1,245 |
| 2025-03-10 | Fakhry Jad | Buy | 14,645 | .58 | 8,494 |
| 2025-03-07 | Fakhry Jad | Buy | 102 | .55 | 56 |
| 2025-03-04 | Fakhry Jad | Buy | 4,000 | .58 | 2,312 |
| 2025-02-28 | Fakhry Jad | Buy | 13,108 | .60 | 7,891 |
| 2025-02-27 | Fakhry Jad | Buy | 385 | .61 | 234 |
| 2025-02-26 | Fakhry Jad | Buy | 6,302 | .61 | 3,844 |
| 2025-02-25 | Fakhry Jad | Buy | 25,033 | .62 | 15,520 |
| 2025-02-24 | Fakhry Jad | Buy | 450 | .62 | 279 |
| 2025-02-20 | Fakhry Jad | Buy | 1,836 | .63 | 1,156 |
| 2025-02-19 | Fakhry Jad | Buy | 49,664 | .67 | 33,374 |
| 2025-02-18 | Fakhry Jad | Buy | 3,222 | .66 | 2,126 |
| 2025-02-04 | Fakhry Jad | Buy | 26,718 | .64 | 16,965 |
| 2025-02-03 | Fakhry Jad | Buy | 2,597 | .64 | 1,649 |
| 2025-01-31 | Fakhry Jad | Buy | 70,685 | .65 | 45,803 |
| 2025-01-27 | Fakhry Jad | Buy | 31,703 | .69 | 21,875 |
| 2023-05-11 | Zheng Yongxiang (Director) | Option Ex | 858 | .00 | 0 |
| 2023-05-11 | Sit Swan (Director) | Option Ex | 858 | .00 | 0 |
| 2023-05-11 | Garlikov Julie (Director) | Option Ex | 858 | .00 | 0 |
| 2023-05-11 | Wu Mijia (Director) | Option Ex | 858 | .00 | 0 |
| 2023-05-11 | Freiman Paul E. (Director) | Option Ex | 858 | .00 | 0 |
| 2023-05-11 | Zheng Yenyou (Director) | Option Ex | 858 | .00 | 0 |
| 2022-11-21 | Kunin Jeffrey (President, DERMAdoctor, LLC) | Sale | 11,920 | 2.10 | 25,090 |
| 2022-11-21 | Kunin Audrey (Chief Product Officer) | Sale | 11,920 | 2.10 | 25,090 |
| 2022-09-14 | Kunin Jeffrey (President, DERMAdoctor, LLC) | Sale | 874,104 | .16 | 138,108 |
| 2022-09-14 | Kunin Audrey (Chief Product Officer) | Sale | 874,104 | .16 | 138,108 |
| 2022-09-14 | Hall Justin (CEO, GC and Director) | Buy | 10,000 | .15 | 1,500 |
| 2022-05-21 | Sit Swan (Director) | Option Ex | 30,000 | .00 | 0 |
| 2022-05-21 | Wu Mijia (Director) | Option Ex | 30,000 | .00 | 0 |
| 2022-05-21 | Freiman Paul E. (Director) | Option Ex | 30,000 | .00 | 0 |
| 2022-05-21 | Zheng Yenyou (Director) | Option Ex | 30,000 | .00 | 0 |
| 2021-12-06 | Jones Andrew D. (CFO) | Buy | 36,765 | .44 | 16,176 |
| 2021-12-06 | Hall Justin (CEO, GC and Director) | Buy | 69,767 | .43 | 29,999 |
| 2021-12-03 | Jones Andrew D. (CFO) | Buy | 8,690 | .44 | 3,823 |
| 2021-12-03 | Kunin Jeffrey (President, DERMAdoctor, LLC) | Buy | 101,650 | .46 | 47,063 |
| 2021-12-03 | Kunin Audrey (Chief Product Officer) | Buy | 101,650 | .46 | 47,063 |
| 2021-12-02 | Kunin Jeffrey (President, DERMAdoctor, LLC) | Buy | 262,369 | .48 | 124,887 |
| 2021-12-02 | Kunin Audrey (Chief Product Officer) | Buy | 262,369 | .48 | 124,887 |
| 2021-12-01 | Kunin Jeffrey (President, DERMAdoctor, LLC) | Buy | 14,848 | .49 | 7,275 |
| 2021-12-01 | Kunin Audrey (Chief Product Officer) | Buy | 14,848 | .49 | 7,275 |
| 2021-11-30 | Kunin Jeffrey (President, DERMAdoctor, LLC) | Buy | 30,000 | .46 | 13,800 |
| 2021-11-30 | Kunin Audrey (Chief Product Officer) | Buy | 30,000 | .46 | 13,800 |
| 2021-11-23 | Kunin Jeffrey (President, DERMAdoctor, LLC) | Buy | 66,133 | .46 | 30,355 |
| 2021-11-23 | Kunin Audrey (Chief Product Officer) | Buy | 66,133 | .46 | 30,355 |
| 2021-11-22 | Kunin Jeffrey (President, DERMAdoctor, LLC) | Buy | 25,000 | .46 | 11,500 |
| 2021-11-22 | Kunin Audrey (Chief Product Officer) | Buy | 25,000 | .46 | 11,500 |
| 2020-08-17 | Wu Mijia (Director) | Sale | 20,000 | 1.35 | 27,000 |
| 2020-08-01 | Fu Jian Ping (10% Owner) | Sale | 1,302,350 | 1.23 | 1,601,890 |
| 2019-06-11 | Fu Jian Ping (10% Owner) | Sale | 380,954 | 3.84 | 1,462,863 |
| 2019-06-11 | Wu Mijia (Director) | Sale | 15,873 | 4.04 | 64,126 |
| 2019-06-11 | Pioneer Pharma (hong Kong) Co Ltd (10% Owner) | Sale | 24,326 | 4.04 | 98,277 |
| 2019-06-10 | Wu Mijia (Director) | Sale | 47,619 | 2.03 | 96,666 |
| 2015-08-20 | Najafi Ramin (Chief Executive Officer) | Buy | 6,000 | .44 | 2,640 |
| 2015-08-19 | Najafi Ramin (Chief Executive Officer) | Buy | 6,000 | .50 | 3,000 |
| 2015-03-03 | Pioneer Pharma (singapore) Pte. Ltd. (10% Owner) | Buy | 2,590,000 | .60 | 1,554,000 |
| 2015-03-03 | Najafi Ramin (Chief Executive Officer) | Buy | 166,666 | .60 | 99,999 |
| 2015-03-03 | Sieczkarek Mark M (Director) | Buy | 166,666 | .60 | 99,999 |
| 2014-12-12 | Stroman David W. (SVP, Ophthalmic Product Devt.) | Buy | 10,000 | .66 | 6,600 |
| 2014-12-12 | Najafi Ramin (Chief Executive Officer) | Buy | 50,000 | .65 | 32,500 |
| 2014-12-12 | Paulson Thomas J (CFO) | Buy | 10,000 | .68 | 6,800 |
| 2014-12-11 | Najafi Ramin (Chief Executive Officer) | Buy | 20,000 | .60 | 12,000 |
| 2014-12-09 | Paulson Thomas J (CFO) | Buy | 10,000 | .67 | 6,700 |
| 2014-12-05 | Najafi Ramin (Chief Executive Officer) | Buy | 25,000 | .65 | 16,250 |
| 2014-12-02 | Najafi Ramin (Chief Executive Officer) | Buy | 18,000 | .71 | 12,780 |
| 2014-12-02 | Wicks Tony D.s. (Director) | Sale | 20,000 | .70 | 14,000 |
| 2014-12-01 | Wicks Tony D.s. (Director) | Sale | 10,000 | .69 | 6,899 |
| 2014-06-04 | Sieczkarek Mark M (Director) | Buy | 4,800 | .89 | 4,272 |
| 2014-05-19 | Sieczkarek Mark M (Director) | Buy | 25,000 | .88 | 22,000 |
| 2014-05-13 | China Pioneer Pharma Holdings Ltd (10% Owner) | Buy | 65,065 | .99 | 64,414 |
| 2014-05-12 | China Pioneer Pharma Holdings Ltd (10% Owner) | Buy | 116,107 | .99 | 114,945 |
| 2014-05-09 | China Pioneer Pharma Holdings Ltd (10% Owner) | Buy | 318,828 | .99 | 315,639 |
| 2014-04-14 | Wicks Tony D.s. (Director) | Option Ex | 52,000 | .56 | 29,120 |
| 2014-03-17 | Dailley Anthony (Director) | Option Ex | 9,000 | .56 | 5,040 |
| 2013-12-02 | Pioneer Pharma (hong Kong) Co Ltd (10% Owner) | Buy | 5,000,000 | 1.14 | 5,699,999 |
| 2013-12-02 | China Pioneer Pharma Holdings Ltd (10% Owner) | Buy | 5,000,000 | 1.14 | 5,699,999 |
| 2013-12-02 | Pioneer Pharma (singapore) Pte. Ltd. (10% Owner) | Buy | 5,000,000 | 1.14 | 5,699,999 |
| 2013-11-14 | China Pioneer Pharma Holdings Ltd (10% Owner) | Buy | 108,156 | 1.02 | 110,319 |
| 2013-09-20 | Li Xinzhou (10% Owner) | Sale | 120,000 | 1.88 | 225,000 |
| 2012-12-11 | Li Xinzhou (Other) | Buy | 120,000 | 1.20 | 144,000 |
| 2012-12-06 | Stroman David W. (SVP, Ophthalmic Product Devt.) | Buy | 10,000 | 1.24 | 12,400 |
| 2012-12-06 | Najafi Ramin (Chief Executive Officer) | Buy | 20,000 | 1.24 | 24,800 |
| 2012-12-06 | Paulson Thomas J (CFO) | Buy | 10,000 | 1.24 | 12,400 |
| 2012-10-31 | Li Xinzhou (10% Owner) | Buy | 1,200,000 | 1.25 | 1,500,000 |
| 2012-10-31 | Naqu Area Pioneer Pharma Co., Ltd. (10% Owner) | Buy | 1,200,000 | 1.25 | 1,500,000 |
| 2012-10-31 | Pioneer Pharma (singapore) Pte. Ltd. (10% Owner) | Buy | 1,200,000 | 1.25 | 1,500,000 |
| 2012-09-27 | Tufts Robert R. (Director) | Option Ex | 28,500 | .56 | 15,960 |
| 2012-09-13 | Li Xinzhou (10% Owner) | Buy | 800,000 | 1.25 | 1,000,000 |
| 2012-05-30 | Paulson Thomas J (CFO) | Buy | 10,000 | .94 | 9,360 |
| 2012-05-29 | Najafi Ramin (Chief Executive Officer) | Buy | 6,000 | .96 | 5,760 |
| 2012-05-25 | Najafi Ramin (Chief Executive Officer) | Buy | 3,500 | .99 | 3,465 |
| 2011-09-12 | Freiman Paul E. (Director) | Buy | 3,000 | .84 | 2,520 |
| 2011-08-26 | Paulson Thomas J (CFO) | Buy | 3,500 | .86 | 3,010 |
| 2011-08-16 | Najafi Family Trust Dated September 13, 2006 (Other) | Buy | 10,000 | .85 | 8,500 |
| 2011-08-15 | Tufts Robert R. (Director) | Buy | 5,000 | .85 | 4,240 |
| 2011-05-27 | Mcpherson T. Alex (Director) | Buy | 6,200 | 1.64 | 10,174 |
| 2011-05-27 | Najafi Ramin (Chief Executive Officer) | Buy | 500 | 1.59 | 797 |
| 2011-05-27 | Khosrovi Behzad (VP Research and Development) | Buy | 1,000 | 1.64 | 1,640 |
| 2011-05-26 | Najafi Ramin (Chief Executive Officer) | Buy | 1,000 | 1.60 | 1,597 |
| 2011-05-24 | Najafi Ramin (Chief Executive Officer) | Buy | 2,552 | 1.71 | 4,363 |
| 2010-08-16 | Freiman Paul E. | Sale | 15,000 | 1.83 | 27,450 |
| 2010-01-04 | Tufts Robert R. | Option Ex | 18,158 | 2.02 | 36,679 |
| 2009-09-03 | Dailley Anthony | Option Ex | 10,000 | .56 | 5,600 |
| 2009-08-31 | Cashion Charles | Buy | 1,000 | 1.90 | 1,900 |
| 2009-08-31 | Tufts Robert R. | Option Ex | 20,000 | .56 | 11,200 |
| 2009-06-11 | Freiman Paul E. | Sale | 25,000 | 2.33 | 58,250 |
| 2009-06-11 | Hixson Harry F Jr | Buy | 25,000 | 2.33 | 58,250 |
| 2008-12-10 | Najafi Family Trust Dated September 13, 2006 | Buy | 500 | 1.14 | 570 |
| 2008-09-12 | Mcpherson T. Alex (Director) | Buy | 200 | 2.00 | 400 |
| 2008-09-12 | Najafi Family Trust Dated September 13, 2006 | Buy | 500 | 1.90 | 948 |
| 2008-09-12 | Paulson Thomas J (CFO) | Buy | 1,900 | 1.94 | 3,676 |
| 2008-09-11 | Najafi Family Trust Dated September 13, 2006 | Buy | 1,000 | 1.92 | 1,924 |
| 2008-09-11 | Khosrovi Behzad (VP Research and Development) | Buy | 500 | 1.95 | 975 |
| 2008-09-11 | Paulson Thomas J (CFO) | Buy | 100 | 1.70 | 170 |
| 2008-09-02 | Najafi Family Trust Dated September 13, 2006 | Buy | 1,000 | 1.98 | 1,980 |
| 2008-08-28 | Najafi Family Trust Dated September 13, 2006 | Buy | 1,000 | 1.92 | 1,920 |
| 2008-08-20 | Najafi Family Trust Dated September 13, 2006 (10% Owner) | Buy | 600 | 1.97 | 1,182 |
| 2008-08-19 | Najafi Family Trust Dated September 13, 2006 (10% Owner) | Buy | 2,000 | 2.02 | 4,030 |
| 2008-04-22 | Tufts Robert R. (Director) | Option Ex | 52,000 | 1.70 | 88,400 |
| 2008-03-14 | Mcpherson T. Alex (Director) | Buy | 1,000 | 2.97 | 2,970 |
| 2008-03-14 | Najafi Family Trust Dated September 13, 2006 (10% Owner) | Buy | 7,200 | 2.67 | 19,244 |
| 2008-03-14 | Khosrovi Behzad (VP, Research & Dev't) | Buy | 1,000 | 2.72 | 2,720 |
| 2008-03-14 | Dailley Anthony (Director) | Buy | 6,000 | 2.75 | 16,500 |
| 2008-03-14 | Paulson Thomas J (Chief Financial Officer) | Buy | 4,000 | 2.70 | 10,800 |
| 2008-03-13 | Tufts Robert R. (Director) | Buy | 2,500 | 2.40 | 6,007 |
| 2007-10-31 | Tufts Robert R. (Director) | Buy | 67,500 | 4.00 | 270,000 |
Insider trading activities including stock purchases, stock sales, and option exercises of NBY listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Novabay Pharmaceuticals, Inc. (symbol NBY, CIK number 1389545) see the Securities and Exchange Commission (SEC) website.